Acorn Wealth Advisors
VVOS icon

Acorn Wealth Advisors’s Vivos Therapeutics VVOS Stock Holding History

Acorn Wealth Advisors’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.18K Hold
14,776
– – ﹤0.01% 302
2026
Q2 		$6.72K Hold
14,776
– – ﹤0.01% 303
2026
Q1 		$17.4K Hold
14,776
– – 0.01% 263
2025
Q4 		$30K Buy
+14,776
New +$36.6K 0.01% 266

Other funds holding VVOS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
Centurion Wealth Management
Centurion Wealth Management Mclean, Virginia $415M AUM 17.23% 1-Year Est. Return
B. Riley Wealth Advisors
B. Riley Wealth Advisors Boca Raton, Florida $2.57B AUM 28.13% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
Nordwand Advisors
Nordwand Advisors Radnor, Pennsylvania $630M AUM 27.11% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
Blue Trust Inc
Blue Trust Inc Alpharetta, Georgia $9.5B AUM 13.02% 1-Year Est. Return
LA
Latitude Advisors Vero Beach, Florida $323M AUM 17.08% 1-Year Est. Return

Acorn Wealth Advisors's VVOS Position: Q3 2026 in Review

Acorn Wealth Advisors held its Vivos Therapeutics (VVOS) position steady in Q3 2026 at 14,776 shares worth $2.18K. The position accounts for ﹤0.01% of the portfolio, ranked #302.

Acorn Wealth Advisors first reported a position in VVOS in Q4 2025 and has held it in 4 quarters since. The position peaked at $30K in Q4 2025. 12 funds tracked by Wall St. Rank hold VVOS as of Q3 2026.

  • Acorn Wealth Advisors held 14,776 shares of Vivos Therapeutics worth $2.18K as of Q3 2026.
  • Acorn Wealth Advisors left its Vivos Therapeutics share count unchanged in Q3 2026.
  • Vivos Therapeutics made up ﹤0.01% of Acorn Wealth Advisors's portfolio in Q3 2026, its #302 holding.
  • Acorn Wealth Advisors first reported a position in Vivos Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Acorn Wealth Advisors's Vivos Therapeutics position peaked at $30K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2026.

Based on Acorn Wealth Advisors's 13F filing for Q3 2026, filed 19 Oct 2026.